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Abstract 
 
Aminoacyl-tRNA synthetases (AARS) are a class of enzymes that catalyze the charging of 
tRNAs with cognate amino acids, a critical step that contributes to the fidelity of protein synthesis. 
Many AARSs also possess noncanonical functions such as regulation of apoptosis, mRNA 
translation, and RNA splicing. Some AARSs have evolved new domains with no apparent 
connection to their charging functions. For example, WHEP domains were originally identified in 
tryptophanyl-tRNA synthetase (WRS), histidyl-tRNA synthetase (HRS), and glutamyl-prolyl-
tRNA synthetase (EPRS). EPRS is a unique bifunctional AARS, found only in higher eukaryotes, 
and consists of glutamyl-tRNA synthetase (ERS) and prolyl-tRNA synthetase (PRS) joined by a 
non-catalytic linker containing three WHEP domains in humans. Two compound heterozygous 
point mutations within human ERS (P14R and E205G) have been identified in the genomes of two 
patients with type 1 diabetes and bone disease. However, the mechanism by which these mutations 
contribute to disease is unknown. Our goal is to determine whether the point mutations affect the 
canonical catalytic activity of EPRS responsible for tRNA charging or noncanonical functions. 
Both P14 and E205 are highly conserved residues located in the GST and catalytic domain, 
respectively. An ERS variant appended to 2.5 WHEP domains (ERS2.5W) has been purified and 
shown to display robust tRNA binding and aminoacylation activity in vitro. The P14R and E205G 
single mutants display the same binding affinity for tRNAGlu as WT ERS2.5W, suggesting that the 
observed defect is at the catalytic step. Whereas the ERS2.5W P14R mutant has near wild-type (WT) 
aminoacylation activity, the ERS2.5W E205G variant has a severe aminoacylation defect. Both 
mutations, however, lead to reduced amino acid activation. Together with a collaborator, we are 
currently characterizing the effect of these two mutations on cell proliferation and the integrated 
stress response. Taken together, this work has important implications for the understanding of 
AARS-related human disease mechanisms and development of new therapeutics. 
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Introduction 
 
Aminoacyl-tRNA synthetases (AARS) are an ancient class of enzymes that catalyze the 
aminoacylation, or “charging,” of a tRNA with its cognate amino acid, a critical step that 
contributes to the fidelity of protein synthesis (Ibba & Söll, 2000). The reaction catalyzed by 
AARSs includes two steps: (1) activation of an amino acid and formation of the aminoacyl 
adenylate intermediate (AA-AMP), and (2) transfer of the amino acid from AA-AMP to the 3¢ end 
of a cognate tRNA. This two-step reaction is illustrated in Figure 1. 
 
AA + ATP ↔ AA-AMP + PPi 
 
AA-AMP + tRNA → AA-tRNA + AMP 
 
 
 
By pairing amino acids with specific anticodon sequences on tRNAs, AARSs are pivotal in the 
physical interpretation of the genetic code. This crucial function of AARSs is evidenced by their 
ubiquity, as they are present in cells from all three domains of life—archaea, bacteria, and eukarya 
(Woese et al., 2000).  
As 20 proteogenic amino acids exist within the cell, organisms possess 20 different 
AARSs, although some exceptions exist. For example, some species of archaea and bacteria have 
been found with as few as 16 AARSs (Bult et al., 1996; Smith et al., 1997). One strategy that 
species lacking a full complement of AARS employ to enable proper translation is the use of 
tRNA-dependent amino acid transformation pathways, such as forming Gln-tRNAGln from Glu-
tRNAGln (Ibba et al., 2000).1 
                                                        
1 AARSs are denoted either by the three letter amino acid abbreviation followed by “RS,” or by 
the single letter amino acid abbreviation followed by “RS.” 
Figure 1. Aminoacylation occurs as a 2-step reaction: activation of amino acid with ATP, 
and transferring of amino acid to tRNA 
 
 
 
6 
AARSs are separated into two classes based on structural and chemical differences. Class 
I AARSs contain a Rossman fold within the catalytic active site and aminoacylate at the 2¢ OH. 
Class II AARSs contain an antiparallel b-fold in the active site and aminoacylate at the 3¢ OH 
(Eriani et al., 1990). In addition, class I AARSs bind ATP in a straight conformation and approach 
tRNA from the minor groove side, while class II AARSs bind ATP in a bent conformation and 
approach tRNA from the major groove side (Arnez & Moras, 1997). Finally, class I AARSs 
primarily function as monomers, while class II AARSs function as multimers (Bullwinkle & Ibba, 
2014). All AARSs contain a catalytic domain and an anticodon binding domain. 
In eukaryotic systems a number of AARSs possess noncanonical functions in addition to 
tRNA charging. These include a host of activities completely unrelated to aminoacylation, such as 
regulation of apoptosis, signal transduction, and RNA splicing (reviewed in Yao & Fox, 2013). 
For example, a proteolysis fragment of TyrRS plays a role in inducing angiogenesis (Wakasugi et 
al., 2002), LeuRS plays a role in tumorigenesis by interacting with the RagD GTPase to stimulate 
the mammalian target of rapamycin (mTOR) pathway (Han et al., 2012), and MetRS plays a role 
in rRNA synthesis through translocation to the nucleus in response to cellular growth signals (Ko 
et al., 2000). 
In higher eukaryotes, a subset of AARSs assemble to form the multi-aminoacyl-tRNA 
synthetase complex (MSC) (Kisselev & Wolfson, 1994). Primitive forms of the MSC have been 
described in archaea (Praetorius-Ibba et al., 2007; Raina et al., 2012), but these complexes do not 
possess any auxiliary proteins. Throughout evolution in eukaryotes, the MSC grew increasingly 
more complex, incorporating accessory proteins that facilitate MSC assembly (Havrylenko & 
Mirande, 2015). The emergence of the MSC throughout evolution is summarized in Figure 2.  
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Although a primitive form of the MSC exists in archaea, distinct differences from eukaryotic 
MSCs suggest a separate origin (Laporte et al., 2014). First, in terms of the mode of assembly, 
eukaryotic MSCs always assemble through protein-protein interaction domains found on auxiliary 
scaffold proteins. Versions of these scaffold proteins in lower eukaryotes are structural homologs 
of the metazoan scaffold proteins, which supports conservation of the MSC in eukarya. In archaea, 
however, assembly is mediated by AARSs themselves. Second, archaeal MSCs consist primarily 
Figure 2. Emergence of the multi-aminoacyl-tRNA synthetase complex (MSC) throughout evolution 
(Havrylenko & Mirande, 2015). The auxiliary proteins which play a structural role in the MSC are shown 
in green. Class I AARSs are shown in blue; class II in red. AARSs are denoted in this figure by the one 
letter symbol of their amino acid substrate. YbaK, shown in yellow, is an autonomous editing protein. 
The MSC grew increasingly more complex throughout evolution in eukaryotes, acquiring auxiliary 
scaffold proteins. Archaeal forms of the MSC possess distinct differences, however, and suggest a 
separate origin. 
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of class II AARSs, whereas eukaryotic MSCs are most abundant in class I AARSs. Class I and 
class II AARSs are themselves evolutionarily distinct, and taking all of these observations together 
suggests that archaeal and eukaryotic MSCs arise from separate origins. 
In humans, the MSC consists of nine different AARS activities in eight proteins— IleRS, 
LeuRS, MetRS, GlnRS, LysRS, ArgRS, AspRS, and Glu-ProRS—along with three non-enzymatic 
scaffold proteins, AARS-interacting multifunctional proteins (AIMPs) (Robinson et al., 2000). 
The current working model of the MSC is shown in Figure 3. 
 
 
AIMP1-3 play a crucial role in maintaining structural integrity of the MSC. For example, depletion 
of AIMP2 triggers a massive disintegration of the MSC (Kim et al., 2002). The MSC is proposed 
to have an overall dimeric structure, joined by aspartyl-tRNA synthetase (DRS) and prolyl-tRNA 
synthetase (PRS) dimers. In addition, glutathione S-transferase (GST) domains shared by AIMP2, 
Figure 3. Proposed structure for the MSC (Cho et al., 2015). The MSC is thought to have an overall 
dimeric structure formed by DRS and PRS dimers. In addition, a gluthione S-transferase (GST) 
tetramer formed by four different MSC components serves as an important platform for MSC 
assembly. 
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AIMP3, glutamyl-tRNA synthetase (ERS), and methionyl-tRNA synthetase (MRS), form a 
heterotetramer that serves as a unique and dynamic platform for MSC assembly (Cho et al., 2015).  
Although the complete function of the mammalian MSC remains unclear, it is thought to 
facilitate substrate channeling and translation as well as controlling the cellular turnover of AARSs 
(Lee et al., 2004). In addition, the MSC serves as a hub for many noncanonical AARS functions. 
While AARSs are usually localized in the MSC for tRNA charging, components of the MSC may 
be inducibly released from the complex to participate in a variety of functions elsewhere in the 
cell (Kim et al., 2014). 
Mutations in AARSs have been linked to a number of diseases, including neuronal 
diseases, cancer, metabolic disorders, and autoimmune disorders (Yao & Fox, 2013; Park et al., 
2008). The diverse connection of AARSs to disease can be seen in the linkage map in Figure 4. Of 
note, these disease-related AARSs include both 
MSC-component AARSs and free AARSs. The 
connection of AARSs to disease may be related 
to either their tRNA charging or noncanonical 
function. For example, diminished 
aminoacylation activity of LysRS has been 
linked to Charcot-Marie-Tooth (CMT) disease, a 
neurological disorder (McLaughlin et al., 2010). 
However, the catalytic activity is normal in 
mutated versions of TyrRS linked to CMT disease, which suggests a noncanonical mechanism 
(Froelich & First, 2011). With the various pattern of enzymatic activity of mutated AARSs in 
disease, the involvement of AARSs in disease pathologies is increasingly gaining attention. 
Figure 4. Linkage map of AARSs with various human 
diseases (Park et al., 2008). 
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Some AARSs have evolved new domains with no apparent connection to their charging 
functions. These include a specialized amino-terminal helix (N-helix), GST domain, leucine zipper 
(LZ) motif, endothelial monocyte-activating polypeptide II (EMAP II) domain, and WHEP 
domains (Guo, Yang, & Schimmel, 2010). Given the lack of function of these domains in tRNA 
charging, it is likely that they play a role in noncanonical functions. In particular, they serve 
important roles in MSC assembly (Cho et al., 2015). WHEP domains were originally identified in 
tryptophanyl-tRNA synthetase (WRS), histidyl-tRNA synthetase (HRS), and glutamyl-prolyl-
tRNA synthetase (EPRS). The latter enzyme is a unique example of a bifunctional AARS, found 
only in higher eukaryotic systems, that consists of two synthetase domains—ERS and PRS—
joined by a non-catalytic linker region containing WHEP domains. Given the unique bifunctional 
nature of EPRS, it serves as an intriguing enzyme to study. 
Our collaborators, Dr. Ron Wek (Indiana University School of Medicine) and Dr. Orly 
Elpeleg (Hadassah Medical Center, Israel), have identified two compound heterozygous point 
mutations—P14R and E205G2—within the ERS portion of the human EPRS genes of two 
Ashkenazi Jewish patients with type 1 diabetes and bone disease. However, the mechanism by 
which these mutations contribute to disease is unknown. In this thesis, I will investigate these point 
mutations in EPRS to determine whether they affect the canonical activity of EPRS responsible 
for tRNA charging or noncanonical functions. This work will enhance our understanding of 
AARS-related human disease mechanisms and may contribute to the development of new 
therapeutics. 
  
                                                        
2 This nomenclature for point mutations indicates the original amino acid, the position of mutation, 
and the new amino acid after mutation. Thus, P14R indicates that a proline at residue 14 is mutated 
to arginine, and E205G indicates that a glutamate at residue 205 is mutated to glycine. 
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Chapter 1: Purification of Human Glutamyl-tRNA Synthetase 
Introduction 
 Human EPRS is a 172 kDa protein that contains four domains: an N-terminal GST domain, 
two catalytic domains (ERS and PRS), and a linker domain containing three tandem WHEP 
domains (Jia et al., 2008) (see Figure 5). Each WHEP domain is 50 amino acids long and possesses 
a helix-turn-helix structure (Cahuzac et al., 2000). GST domains are found in a number of different 
AARSs and other translational factors (Koonin et al., 1994; Guo & Yang, 2014), and they are 
thought to play a role in protein assembly and folding (Cho et al., 2015). ERS is a class I AARS, 
while PRS is a class II AARS. 
Numerous noncanonical functions of EPRS are known. Phosphorylation at specific serine 
residues within the linker promote participation of EPRS in the GAIT (interferon-g-activated 
inhibitor of translation) system, leading to silencing of inflammation-related mRNAs (Arif et al., 
2009). Another site-specific phosphorylation in the linker directs antiviral immune response during 
infection of RNA viruses (Lee et al., 2016).  EPRS also facilitates long chain fatty acid uptake in 
insulin-treated adipocytes (Arif & Fox, 2017). Critical to all of these noncanonical functions is the 
release of EPRS from the MSC via linker phosphorylation. 
Full-length human EPRS has never before been purified. Previous attempts have 
encountered either poor expression or solubility (Lei et al., 2015). However, individual 
components ERS and PRS have been purified. Though purified PRS displayed robust 
aminoacylation activity, purified ERS displayed very weak catalytic activity (Halawani et al., 
2018). To lay the groundwork for studying the ERS point mutations P14R and E205G, we first 
sought to purify an active wild-type (WT) ERS construct. 
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Materials and Methods 
Plasmid Construction 
The plasmid encoding human EPRS was a gift from Dr. Paul Fox (Cleveland Clinic). The 
backbone vector, SUMO pRSF MBP, was a gift from Dr. Kotaro Nakanishi (Ohio State). Three 
ERS genes, ERS (aa. 1-687), ERSRC (aa.1-749), and ERS2.5W (aa.1-929), were cloned into the 
SUMO pRSF MBP vector between SalI and NotI restriction sites. Cloning was confirmed by 
Sanger sequencing. 
 
Protein Preparation 
All three human ERS variants were purified using the same procedure. Escherichia coli 
BL21(DE3)RIL was transformed with the ERS-encoding plasmid and protein expression was 
induced with 0.1 mM isopropyl b-D-thiogalactopyranoside (IPTG) at 16 °C overnight. Cells were 
harvested by centrifugation and resuspended in lysis buffer (8 mL / g cell pellet) (500 mM NaCl, 
25 mM Tris-HCl pH 8, 5 mM imidazole, 5% glycerol, 3 mM 2-mercaptoethanol, and protease 
inhibitor). Cells were lysed by incubation with 10 mg/mL lysozyme on ice for 30 min and moderate 
sonication. To remove nucleic acid, cell lysate was incubated with 0.5% v/v polyethyleneimine 
(PEI) on ice for 30 min. Precipitated nucleic acid and cell debris were removed by centrifugation 
for 30 min at 15,000 g at 4 °C. Proteins were precipitated with 375 mg/mL ammonium sulfate, 
resuspended in 20 mL lysis buffer, and then filtered through a 0.45 µm syringe filter. The filtered 
cell lysate was loaded onto a nickel (II) column, equilibrated with lysis buffer. The column was 
washed with lysis buffer, and the protein was then eluted with buffers containing 10-100 mM 
imidazole. Elution fractions containing ERS—as confirmed by SDS-PAGE analysis—were pooled 
and dialyzed with SUMO protease overnight. The digested protein was concentrated and further 
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purified using size-exclusion chromatography (SEC) on a Superdex 200 16/60 column. Proteins 
were stored at -20 °C at approximately 100 µM in 40% glycerol. 
 
Size-exclusion chromatography / multi-angle light scattering (SEC/MALS)  
 
Protein samples were run on the Akta Pure 25M (GE) coupled to a Dawn Helios 8+ (Wyatt) 
multi-angle light scattering system equipped with an Optilab TrEX refractive index detector and 
Wyatt QELS quasi-elastic light scattering detector (Wyatt). Approximately 100 µg protein in 500 
µL total volume was separated over a Superose 6 Increase column (GE) at 0.4 mL/min. Molecular 
weights were calculated using Astra 7 software. 
 
RNA Preparation 
 
The transcription template for human tRNAGlu (TTC) was prepared from a pIDTsmart 
plasmid through digestion with FokI restriction endonuclease. The tRNA was prepared via in vitro 
transcription with T7 RNA polymerase using a standard protocol (Milligan & Uhlenbeck, 1989) 
and run on a 12% urea-PAGE gel. The desired band was excised, crushed, and soaked in RNA 
elution buffer (0.5 mM NH4OAc, 1 mM EDTA) overnight at 37°C with shaking at 200 rpm. The 
RNA was then isolated through butanol extraction of the supernatant and subsequent ethanol 
precipitation.  
 
Aminoacylation Assays 
 
Aminoacylation assays were performed as previously described (Francklyn et al., 2008). 
The tRNAGlu was folded in water by heating at 80 °C for 2 min, 60 °C for 2 min, adding MgCl2 
(final concentration 10 mM), and incubating for 5 min at room temperature followed by incubation 
on ice for a minimum of 30 min. To initiate the reaction, ERS (100 nM) was added to 4 µM 
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tRNAGlu at 37°C in reaction cocktail (20 mM Tris pH 7.5, 20 mM KCl, 10 mM MgCl2, 0.1 mg/mL 
BSA, 4 mM DTT, 4 mM ATP, 20 µM glutamic acid, 0.3 µCi/µL 3H-glutamic acid). 
 
 
Results and Discussion 
Section I: Protein Purification and Oligomerization Analysis 
We initially had difficulty purifying full-length ERS (aa. 1-687) due to the protein 
appearing in inclusion bodies (Figure 5B, right panel). We hypothesized that the linker region 
facilitates folding of ERS and solubilization of the protein since ERS exists in vivo with a linker 
joining it to PRS. Therefore, we designed two maltose-binding protein (MBP)-tagged extended 
ERS constructs: ERSRC and ERS2.5W. The latter construct was designed based on a previous finding 
that ERS2.5W exists in cells as a caspase-3 cleavage product (Halawani et al., 2018). In addition, 
we included the small ubiquitin-like modifier (SUMO) solubility enhancer. These constructs are 
shown in Figure 5A. As shown in Figure 5B, the presence of the linker domain in the ERSRC and 
ERS2.5W constructs enhanced solubility of the protein and thereby facilitated protein purification. 
Though a few low-molecular weight impurities remained present after size-exclusion 
chromatography, the final proteins were estimated to be ~90% pure (Figure 5C). 
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Figure 5. Inclusion of the linker domain in the WT ERS construct enhanced solubility of the protein, 
enabling purification. (A) ERS constructs, referenced to full-length EPRS. Tags: His-tag (purple), SUMO 
(orange), MBP (blue). (B) Proteins after IPTG induction at 16 °C overnight and lysis by sonication, shown 
on Coomassie-stained SDS-PAGE gels visualized with UV light. (C) Final purified proteins (4 µg). All proteins 
retained an N-terminal MBP-tag after purification. 
 
To assess the oligomerization state of the ERS proteins in solution, we performed an 
SEC/MALS experiment. As shown in Figure 6, only a single peak was observed for each protein, 
indicating that both proteins exist as monomers in solution. Theoretical molecular weights (MW) 
for MBP-tagged ERS2.5W and ERSRC are ~ 146 kDa and 127 kDa, respectively. These are 
consistent with MWs calculated based on the retention volume (Figure 6). These results are also 
consistent with the expectation based on the known oligomeric state of class I synthetases 
(Bullwinkle & Ibba, 2014) and with models of the MSC, where although EPRS exists as a dimer 
through direct contact between the PRS domains, the ERS portion does not form a self-dimer (Cho 
et al., 2015) (see Figure 3). 
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Figure 6. SEC/MALS chromatogram of purified WT ERS2.5W and ERSRC. Both proteins exist as monomers in 
solution. MWs calculated from the retention volume are consistent with theoretical MWs for both ERS2.5W 
and ERSRC. Experiment performed by Dr. William Cantara.  
 
Section II: Aminoacylation Activity 
 
 As discussed in the introduction of this chapter, previously purified ERS2.5W displayed poor 
catalytic activity (Halawani et al., 2018). We next tested our purified WT ERS constructs to 
determine their aminoacylation activity. Results of these charging assays revealed that both ERSRC 
and ERS2.5W are active in tRNAGlu charging (Figure 7). We estimate that our proteins are 50 - 80 
times more active in aminoacylation than the ERS2.5W preparation reported in Halawani et al 
(2018). 
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Although WT ERSRC achieves a greater degree of product formation than ERS2.5W, the 
slope for initial rate is nearly identical between the two proteins.  This suggests that the two 
proteins have similar activities. A more detailed kinetic analysis is carried out in Chapter 2.  
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Figure 7. Both WT ERSRC and WT ERS2.5W are active in tRNAGlu charging. 
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Chapter 2: Characterization of ERS Point Mutations Implicated in 
Human Disease 
 
Introduction 
 According to data from the Human Gene Mutation Database (HGMD), there are six total 
reported EPRS mutations that have been linked to disease. Mutation R339E is linked to autism 
spectrum disorder (Iossifov et al., 2014). Five other mutations—R339*, P1115R, M1126T, 
P1160S, and T1223Lfs3*3— are linked to hypomyelinating leukodystrophy and may be related to 
reduced translation ability through reduced protein availability, abnormal MSC assembly, and/or 
abnormal aminoacylation (Mendes et al., 2018). 
Compound heterozygous EPRS mutations, P14R and E205G, were discovered by our 
collaborators in patients with type 1 diabetes and bone disease. Residue P14 is located in the GST 
domain, and E205 is in the catalytic domain. The location of these residues within the full-length 
domain structure of EPRS is shown in Figure 8. 
 
 
 
                                                        
3 R339* is a nonsense mutation, meaning the mutation introduces a premature stop codon 
(indicated by “*”). T1223Lfs3* is a frameshift mutation, where T at position 1223 is changed to 
L, and a stop codon is introduced 3 codons downstream. 
Figure 8. Full-length domain structure of EPRS highlighting residues P14 and E205. P14 lies in the GST 
domain, while E205 lies in the catalytic domain. 
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 This chapter will characterize these ERS point mutations, exploring sequence homology 
and measuring their effect on tRNA binding, aminoacylation, and amino acid activation. 
 
 
Materials and Methods 
 
Phylogenetic Studies 
 
 Multi-sequence alignments were generated using the Clustal Omega multiple sequence 
alignment tool. Sequences were obtained from the NCBI database. A homology model for ERS 
was created by Dr. William Cantara based on E. coli GlnRS using the ExPASy SWISS-MODEL 
server and edited with PyMOL software. 
 
Plasmid Construction 
 For details on cloning, see “Plasmid Construction” in Chapter 1. Mutagenesis for the P14R 
mutant, E205G mutant, and the double mutant P14R + E205G was accomplished using site-
directed, ligase-independent mutagenesis (SLIM). Primers were designed by Danni Jin and the 
mutagenesis performed as described (Chiu et al., 2008). Mutations were confirmed by Sanger 
sequencing. All mutations were created in the context of the ERS2.5W construct. The E205G 
mutation was also created in the context of the ERSRC construct. 
 
Protein Preparation 
  
For details on protein preparation, see “Protein Preparation” in Chapter 1.  
 
RNA Preparation 
  
For details on RNA preparation, see “RNA Preparation” in Chapter 1.  
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Fluorescent RNA Labeling 
  
The tRNA was labeled with fluorescein-5-thiosemicarbazide (FTSC) at the 3¢ end as 
described (Rye-McCurdy et al., 2015). The concentration and labeling efficiency were determined 
by measuring the absorbance at 260 nm and 495 nm, using the following extinction coefficients: 
e495nm = 85,000 M-1cm-1 (FTSC) and e260nm = 60.4 ´ 104 M-1cm-1 (tRNAGlu). 
 
Fluorescence Anisotropy Binding Assays 
  
The 3¢ FTSC-labeled tRNAGlu was folded in 50 mM Tris (pH 8) buffer by heating at 80 °C 
for 2 min, 60 °C for 2 min, adding MgCl2 (final concentration 1 mM), and incubating for 5 min at 
room temperature followed by incubation on ice for a minimum of 30 min. The fluorescence 
anisotropy (FA) binding assays were then carried out as previously described (Rye-McCurdy et 
al., 2015). RNA (5 nM) was incubated with serially diluted ERS at room temperature for 30 min 
in FA binding buffer (20 mM Tris pH 8, 35 mM NaCl, 1 mM MgCl2). The data were fit to the Hill 
equation and Kd values were derived from three independent experiments. 
 
Aminoacylation Assays 
  
Aminoacylation assays were performed as previously described (Francklyn et al., 2008). 
For details on tRNA folding, see “Aminoacylation Assays” in Chapter 1. Assays were performed 
under kcat/KM conditions with 25 nM ERS2.5W (WT) or 100 nM ERS2.5W (mutants P14R, E205G, 
and P14R + E205G) and 0.5 µM tRNAGlu at 37 °C in reaction cocktail (20 mM Tris pH 7.5, 20 
mM KCl, 10 mM MgCl2, 0.1 mg/mL BSA, 4 mM DTT, 4 mM ATP, 20 µM glutamic acid, 0.3 
µCi/µL 3H-glutamic acid) for 2 min with time points every 20 sec. 
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To determine kinetic parameters vmax and KM, assays were performed with 100 nM ERS2.5W 
and tRNAGlu concentrations ranging from 0.25 - 8 µM (WT) or 0.5 - 16 µM (mutants). Time points 
were taken every 20 sec with a time course of 2 min. 
 
Preparation of Unchargeable tRNA 
  
To prepare a tRNA that could not be aminoacylated, the 3¢ end of tRNAGlu was oxidized 
with sodium periodate (NaIO4) as described (Rye-McCurdy et al., 2015). The oxidized tRNA was 
then stabilized by a two-step sequence of reactions (protocol courtesy of Dr. Craig Forsyth). First, 
the tRNA was reacted with 20-fold molar excess of benzylamine in 25 mM Tris-HCl pH 6.3 with 
intermittent vortexing at room temperature for 60 min. The tRNA was then reacted with 20-fold 
molar excess of sodium cyanoborohydride and vortexed intermittently at room temperature for 60 
min. The RNA was purified with a Roche G-25 spin column and ethanol precipitated to yield the 
final 3¢-end defective tRNAGlu-ox product. 
 
ATP-PPi Exchange Assays 
  
The amino acid activation step of the aminoacylation reaction was assessed using the ATP-
PPi exchange assay (Francklyn et al., 2008). The tRNA was pre-bound to ERS by incubation at 
room temperature for 30 min. Reaction conditions were 20 mM Tris-HCl pH 7.5, 20 mM KCl, 10 
mM MgCl2, 4 mM DTT, 0.1 mg/mL BSA, 4 mM ATP, 2mM PPi + [32P]-PPi, 10 µM 3¢-end 
defective tRNAGlu-ox, 3 µM ERS, and 1.6 mM glutamic acid at 37 °C. Time points were taken 
every 6 min over a 30 min time course by quenching 2 µL of reaction into 8 µL of 200 mM NaOAc 
pH 5. Spots (2 µL) were placed on a TLC plate and eluted in 750 mM KH2PO4, 4 M urea, pH 3.5. 
Plates were exposed to a phosphor screen and visualized on a Typhoon scanner. 
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Results and Discussion 
 
Section I: Sequence Conservation of the Mutated Residues 
 
 We performed a sequence alignment to gain insight into the extent of conservation of the 
mutated residues. The multi-sequence alignment in Figure 9A demonstrates a high degree of 
conservation among eukaryotic species at the mutated residues. 
 
 
The high degree of conservation suggests that these amino acids are likely playing an important 
role in the function of the enzyme. If they are mutated, as in the case of the two patients reported 
to us, cellular and/or physiological function is likely to go awry. According to structures and 
sequence alignments of the EPRS GST domain, the P14 residue is located at the N-terminus of the 
Figure 9. Sequence conservation of the mutated residues and their locations in human ERS. (A) Sequence 
alignment showing a high degree of conservation at residues P14 and E205 among a number of different 
eukaryotes. (B) Top: Location of the P14 residue in the GST domain. Image adapted from Cho et al., 2015. 
Bottom: Homology model of ERS domain based on E. coli GlnRS, showing E205 is localized to the ATP-
binding pocket of the catalytic domain. Model sequence identity = 36%; sequence similarity = 38%. Model 
generated by Dr. William Cantara. 
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a1 helix (Cho et al., 2015) (Figure 9B, top panel). Previous phylogenetic analyses of GST domains 
in AARSs showed the GST domain to appear in ERS around the emergence of eukaryotes (Guo, 
Schimmel, & Yang, 2010). As GST domains facilitate protein folding and protein-protein 
interactions, we hypothesize that mutation of the P14 residue may play an important structural role 
in the folding of this domain and affect association of EPRS with the MSC. A homology model 
based on E. coli GlnRS reveals that the E205 residue is nestled within the ATP-binding pocket of 
the catalytic domain (Figure 9B, bottom panel). Given that the amino acid glycine lacks a side 
chain, it is possible that the E205G mutation widens the ATP-binding site, reducing the ATP 
binding affinity. Therefore, we hypothesize that the E205G mutation will have a negative impact 
on aminoacylation. 
 
Section II: tRNA Binding 
 
The binding of tRNA to AARS is a pivotal step in the charging of tRNA. We performed 
FA binding assays to study the binding of tRNAGlu to our ERS proteins. We first studied binding 
of WT ERSRC and ERS2.5W to tRNAGlu, as this would provide insight into whether our constructs 
would be effective for study of the P14R and E205G point mutations.  As seen by the graphs in 
Figure 10A-B and the table in Figure 10F, WT ERS2.5W bound tRNAGlu with approximately 4-fold 
greater affinity than WT ERSRC. This suggests that the WHEP domains of EPRS play a role in 
facilitating tRNAGlu binding. 
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Figure 10. Fluorescence anisotropy assays measuring binding of tRNAGlu to WT and mutant ERS 
constructs. (A) ERS2.5W WT, (B) ERSRC WT, (C) ERS2.5W E205G, (D) ERSRC E205G, (E) ERS2.5W P14R, (F) Table 
summarizing Kd values for all proteins. 
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It is known that WHEP domains can bind RNA. For example, the WHEP domains of EPRS have 
previously been shown to bind the GAIT element RNA (Jia et al., 2008). In addition, purified 
EPRS linker is able to bind tRNALys (Jia et al., 2008).  It is also known that the WHEP domain of 
MetRS has a tRNA-sequestering function (Kaminska et al., 2001). The linker region of EPRS is 
highly basic, and it is likely that it interacts with tRNAs non-specifically. Thus, it is likely that the 
presence of 2.5 WHEP domains facilitates the binding of tRNAGlu to ERS by increasing the total 
local concentration of tRNA. This hypothesis of non-specific interaction could be tested by 
performing FA binding assays with noncognate tRNA. 
Having established that WT ERS2.5W binds tRNAGlu with greater affinity than ERSRC, we 
created the P14R and E205G point mutations within the context of the ERS2.5W construct and 
performed additional FA binding assays. As neither mutation lies within the anticodon binding 
domain, we hypothesized that the mutations would not affect tRNA binding affinity. As seen in 
Figure 10C, E, and F, our results indicate that indeed neither mutation has an effect on tRNAGlu 
binding, as both the ERS2.5W P14R and ERS2.5W E205G mutants bind tRNAGlu with the same 
affinity as their WT counterpart. It is important to note that the N-terminal MBP tag may alter 
tRNA binding affinity so that the reported Kd values do not reflect absolute physiological values; 
however, all constructs maintain the MBP tag, so comparisons between the constructs are still 
valid. In addition, the Kd values found for the ERS2.5W constructs are comparable to previous values 
determined for untagged E. coli ERS (Chongdar et al., 2015). 
We also performed FA binding experiments with an ERSRC E205G mutant. As seen in 
Figure 10D and 10F, this protein bound tRNAGlu with the same affinity as WT ERSRC. The 
implication of this result is two-fold. First, this result supports our earlier data that the presence of 
the E205G mutation does not affect tRNAGlu binding affinity. Second, even though the E205G 
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mutation is present in this construct, the protein still bound tRNAGlu with lower affinity than when 
2.5 WHEP domains are present. Thus, this data supports our observation that the presence of 2.5 
WHEP domains in ERS enhances tRNAGlu binding. 
 
 
Section III: Aminoacylation 
 
As described earlier, both WT ERSRC and ERS2.5W are active in tRNAGlu charging, with 
similar activities (see Figure 7). We next studied the aminoacylation activity of the ERS mutants. 
We hypothesized that the E205G mutation, but not P14R, would contribute to a defect in 
aminoacylation. As P14 lies in the GST domain, it is unlikely to affect aminoacylation. In contrast, 
E205 lies in the ATP binding pocket of the catalytic domain, likely playing a role in the enzyme’s 
catalytic function. 
To gain an initial indication of the enzymes’ activities, we performed aminoacylation 
assays under kcat/KM conditions (A more detailed kinetic analysis is described below). At low 
substrate concentrations ([S] << KM), the initial rate of reaction is proportional to kcat/KM. We 
performed assays at 0.5 µM tRNAGlu to achieve these conditions. As shown in the initial rate data 
plotted in Figure 11A, the P14R mutant displays near-WT aminoacylation activity, whereas the 
E205G variant has a severe aminoacylation defect. Results of these assays are summarized in 
Figure 11B. As demonstrated by the comparisons in fold decrease of kcat/KM, the E205G 
mutation—whether as a single mutation or in combination with P14R as a double mutant—
significantly reduces aminoacylation activity. These results are consistent with our hypothesis.  
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Again, it is important to note that activities of these proteins may be altered due to the presence of 
the N-terminal MBP tag. However, WT ERS is still active with the MBP tag (Figure 7, Figure 11). 
Furthermore, the calculated kcat/KM for WT ERS2.5W is actually comparable to that of previously 
purified untagged ERS of E. coli (Sylvers et al., 1993), Pseudomonas aeruginosa (Hu et al., 2015), 
and rice (Oryza sativa) (Yang et al., 2018). In addition, all of the ERS constructs compared in 
Figure 11 maintain the MBP tag, so even if the determined parameters do not reflect absolute 
physiological values, the relative values are still valid, allowing us to assess the effects of the 
mutations on aminoacylation. 
We also performed preliminary aminoacylation reactions at varying tRNAGlu concentration 
to determine kinetic parameters vmax and KM for each of the enzymes. Results of these assays are 
shown in Figure 12 A-D.  
Figure 11. Aminoacylation activities of ERS2.5W WT and mutants. (A) Aminoacylation assays performed 
under kcat/KM conditions with 25 – 100 nM enzyme and 0.5 µM tRNAGlu. N = 3 or 4. (B) Summary table of 
kinetic results. ERS2.5W P14R has near-WT aminoacylation activity, while ERS2.5W E205G has a severe 
aminoacylation defect. 
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As shown in Figure 12A, the concentration range used for tRNAGlu (0.25 - 16 µM) was 
suitable for WT ERS2.5W but not ideal for ERS2.5W P14R and ERS2.5W E205G. In particular, for 
ERS2.5W P14R, the reaction rates for 2-16 µM tRNAGlu were nearly identical. This suggests that 
the reaction rate begins to plateau at approximately 2 µM tRNAGlu, approaching vmax, and thus the 
Figure 12. (A) Preliminary aminoacylation assays at varying tRNAGlu concentration to determine kinetic 
paramters for each of the enzymes. For WT ERS2.5W, tRNAGlu was varied from 0.25 - 8 µM, while tRNAGlu 
was varied from 0.5 - 16 µM for ERS2.5W P14R and ERS2.5W E205G. (B) Inverse reciprocal plots for the 
aminoacylation reactions shown in A. (C) Direct fits to the Michaelis-Menten equation. (D) Summary 
of kinetic parameters obtained for ERS2.5W WT and ERS2.5W P14R based on the fits shown in panel C. 
Experiments performed by Danni Jin. 
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KM lies below this value. Lineweaver-Burk plots are shown in Figure 12B.  Since linearization-
based approaches can be subject to high degrees of error, we also fit the kinetic data directly to the 
Michaelis-Menten equation, 𝑣 = 	 &'()[+]-./[+] (Figure 12C). From this fit, we obtained kinetic 
parameters for WT ERS2.5W and ERS2.5W P14R, but the data was too poor to do so for ERS2.5W 
E205G. 
Figure 12D compares the preliminary assay results for WT and P14R ERS2.5W (1 trial). 
Although the individual parameters are different, the values of vmax/KM are nearly identical for WT 
and P14R, which suggests that the two enzymes have similar catalytic efficiency. Based on these 
preliminary data, we conclude that the P14R mutation does not significantly affect catalytic 
efficiency for the aminoacylation reaction. However, more trials need to be performed in order to 
confirm this observation. 
Of note, the calculated KM for ERS2.5W P14R shown in Figure 12D is quite low. If KM for 
ERS2.5W P14R is confirmed to be this low after further trials, the results in Figure 11 A-B are called 
into question. Those results depend on [S] << KM, and 0.5 µM tRNAGlu is not low enough to 
achieve this condition for ERS2.5W P14R if it has a KM < 0.3 µM. 
 
 
Section IV: Amino Acid Activation 
 
Aminoacyl-tRNA synthetases catalyze aminoacylation of tRNA in two steps. The first step 
is the formation of an aminoacyl adenylate complex, and the second is the attachment of the amino 
acid to tRNA (see “Introduction,” Figure 1). The ATP-PPi exchange assay is designed to measure 
enzyme activity by quantitating the reversible first step in this process. 32P-PPi is included in the 
assay mixture and in the presence of AARS is converted into 32P-ATP. 
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Unlike most AARSs, ERS, along with GlnRS, ArgRS, and class I LysRS, requires the 
presence of tRNA for the amino acid activation step. This poses a challenge for the assay because 
the presence of chargeable tRNA interferes with the assay. Chargeable tRNA will accept an amino 
acid transferred from aa-AMP, thereby depleting aa-AMP from the system and shifting the 
equilibrium for the activation reaction. Thus, it was important to generate a tRNA that did not get 
charged but that could still facilitate the amino acid activation reaction. 
A previous study of E. coli GlnRS designed a suitably modified tRNAGln through use of a 
modified synthetic tRNA, ligating chemically synthesized tRNA half-molecules to form 
tRNAGln2¢H  (Gruic-Sovulj et al., 2005). After trying multiple methods, we decided to use a tRNAGlu 
with its 3¢ end oxidized with sodium periodate and stabilized with benzylamine and sodium 
cyanoborohydride. An outline of the reaction is provided in Figure 13A. A charging assay 
confirmed that this modified tRNA—tRNAGlu-ox—was defective in tRNA charging (Figure 13B). 
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Figure 13. (A) Reaction scheme for oxidizing and stabilizing the 3¢ terminal adenosine, A76, of tRNAGlu.  
(B) A charging assay revealed that tRNAGlu-ox is defective for aminoacylation. 
 
 
As seen in Figure 14, WT ERS2.5W displayed amino acid activation, consistent with 
previous trials. However, both the E205G and P14R mutant were defective in amino acid 
activation and activity could not be detected under the conditions of this assay.  
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The result of this assay for E205G was consistent with our hypothesis, as E205 is proposed 
to be located in the ATP-binding pocket and the mutation likely abrogates the enzyme’s ability to 
interact with ATP. However, the result for P14R was surprising. Even though P14R does not 
significantly affect aminoacylation, it appears to be having an effect on amino acid activation. This 
deficiency in activation could perhaps be the explanation for the very slight defect in 
aminoacylation seen in Figure 11A-B. Plots obtained by quantification of the phosphor transfer 
Figure 14. ATP-PPi exchange assay with WT and mutant ERS2.5W. (A) WT ERS2.5W was active in amino acid 
activation, but mutant P14R and E205G ERS2.5W were not. Assays were performed with 3 µM ERS2.5W and 
10 µM tRNAGlu-ox. (B) Formation of ATP is nearly linear for WT ERS2.5W but completely defective for P14R 
and E205G mutants. Plots were generated by quantifying the phosphor transfer image of the TLC plates 
shown in panel A. Plot courtesy of Danni Jin. 
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show that the amount of 32P-ATP synthesized increased substantially in the presence of WT 
ERS2.5W (Figure 14B). These results are comparable to those in ATP-PPi exchange assays 
performed with E. coli GlnRS (Uter et al., 2005). No ATP was formed in the presence of the P14R 
and E205G mutants, however. It is likely that sensitivity for this assay was not high enough to 
detect whatever activation may be occurring in the P14R mutant. 
 Previous unpublished data from our lab demonstrate cases where LysRS mutants, although 
displaying robust aminoacylation activity, appear defective in amino acid activation when studied 
with the ATP-PPi exchange assay. Therefore, although our result is unusual, it is not completely 
unprecedented. Under steady-state kinetic conditions, the rate-limiting step for class I AARSs is 
product (aminoacyl-tRNA) release (Zhang et al., 2006). That may help explain the discrepancy 
between the aminoacylation and amino acid activation results for the ERS2.5W P14R mutant. If 
there is a difference in kinetics between WT and P14R at the activation step, that would not be 
evident in the aminoacylation assay, as the rate-limiting step informing kinetic parameters is 
product release, not activation. When the assay is restricted to observing the activation step, as 
with the ATP-PPi exchange assay, then differences in kcat may become more readily apparent. 
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Conclusions and Future Directions 
 
 In this work, we successfully purified recombinant human ERS and showed that it was 
active in aminoacylation with the oligomerization state in solution in agreement with other class I 
synthetases and with proposed structures for the MSC. We found that the presence of 2.5 WHEP 
domains increased protein solubility and enhanced tRNAGlu binding. We have shown the residues 
P14 and E205 to be highly conserved, indicating an important role in the functioning of the 
enzyme. Neither the P14R nor the E205G mutation affects tRNAGlu binding affinity. The E205G 
mutation, but not P14R, contributes to a defect in aminoacylation. While the E205G mutant is 
defective in amino acid activation, the P14R mutant is surprisingly defective in this as well. Taking 
these findings all together, the disease phenotypes observed in the patients may be linked to a 
defect in tRNA charging due to the E205G mutation. The exact role of the P14R mutation remains 
unclear and requires further study. 
Unpublished data from our lab has shown that a P14R mutant displays increased 
proteolysis in HEK293T cells relative to the WT protein or the E205G variant, with a significantly 
increased amount of a C-terminal fragment with MW ~60 kDa observed. This demonstrates that 
the P14R mutation may contribute to a long-range structural effect. Therefore, it is possible that 
conformational changes induced by the P14R mutation could have a rate-limiting effect on the 
amino acid activation step. 
 In our future work, we plan to investigate folding of a WT and P14R mutant of an ERS 
GST construct through circular dichroism (CD) spectroscopy. To examine possible long-range 
effects of this mutation, we will also perform CD studies of the WT and P14R ERS2.5W proteins. 
In addition, we plan to perform rescue experiments for a cell proliferation defect in EPRS 
knockdown cells with WT and mutants. In collaboration with Dr. Ron Wek (Indiana University), 
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we plan to perform western blotting experiments to determine if truncated EPRS exists in patient 
cells, and to assess levels of uncharged tRNAGlu in patient cells. Finally, the primary noncanonical 
pathway we plan to investigate is how these mutations affect the integrated stress response (ISR).  
 In response to diverse stress stimuli, cells activate the ISR to restore homeostasis. The key 
feature of the ISR is phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2a) by 
an eIF2a kinase. There are four different types of eIF2a kinases, and each responds to distinct 
environmental and physiological stresses (Pakos-Zebrucka et al., 2016). General control 
nonderepressible 2 (GCN2) is an eIF2a kinase that is activated in response to amino acid 
starvation. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is another eIF2a 
kinase, but is activated in response to endoplasmic reticulum (ER) stress resulting from 
accumulation of unfolded proteins (Pakos-Zebrucka et al., 2016). Although the ISR is generally a 
pro-survival, homeostatic program, severe stress can drive signaling toward cell death. 
 We hypothesize that the EPRS mutants sensitize cells to stress, leading to higher levels of 
the ISR that can diminish cell viability. A defect in ERS aminoacylation leads to accumulation of 
uncharged tRNAGlu, which is analogous to amino acid starvation. Thus, in the case of the E205G 
mutation, the ISR is likely stimulated through activation of GCN2. The P14R mutation is likely to 
have an effect on protein folding, and we therefore propose that this mutation induces the ISR 
through activation of PERK. This hypothesis is summarized in Figure 15. This is certainly a 
possibility for disease etiology, as ER stress and activation of PERK have been implicated in 
autoimmune-mediated b-cell destruction in type 1 diabetes (Zhong et al., 2012). Alternatively, 
P14R may contribute to disease through the mammalian target of rapamycin (mTOR) signaling 
pathway. The mTOR pathway serves as a key regulator for cellular growth, metabolism, 
proliferation, and survival (Laplante & Sabatini, 2009). The mTOR complex 1 (mTORC1) works 
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together with protein kinase S6 kinase 1 (S6K1) in the mTORC1-S6K1 axis. EPRS is known to be 
phosphorylated by mTORC1-S6K1, which releases EPRS from the MSC to facilitate fatty acid 
uptake (Arif et al., 2017). Prolonged ER stress activates mTORC1 (Guan et al., 2013); therefore, 
it is possible that this activation of mTORC1 also leads to inducible release of EPRS from the 
MSC. If the P14R mutation affects association of EPRS with the MSC, this potential interaction 
with mTORC1 could be dysregulated, creating downstream effects that lead to disease. 
 
 
 
 
  
Figure 15. Hypothesis of the integrated stress response (ISR) pathway to disease from EPRS 
mutations E205G and P14R. E205G may lead to accumulation of uncharged tRNAGlu, causing amino 
acid starvation, and activation of GCN2. P14R may lead to protein misfolding, causing ER stress 
and activation of PERK. Both GCN2 and PERK phosphorylate eIF2a, initiating the ISR. This leads to 
a decrease in global translation, and with severe enough stress, this may lead to diminished cell 
viability and disease. 
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